Zobrazeno 1 - 10
of 535
pro vyhledávání: '"A O, Trounson"'
Autor:
Vera J. Evtimov, Maree V. Hammett, Aleta Pupovac, Nhu-Y N. Nguyen, Runzhe Shu, Carrie Van Der Weyden, Robert Twigger, Ian T. Nisbet, Alan O. Trounson, Richard L. Boyd, H. Miles Prince
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e36298- (2024)
Purpose: Current monoclonal antibody-based treatment approaches for cutaneous T cell lymphoma (CTCL) rely heavily on the ability to identify a tumor specific target that is essentially absent on normal cells. Herein, we propose tumor associated glyco
Externí odkaz:
https://doaj.org/article/27ce761717be41dd8d994e1eede61138
Publikováno v:
Frontiers in Immunology, Vol 13 (2022)
Chimeric antigen receptor (CAR)-T therapy has demonstrated remarkable outcomes for B cell malignancies, however, its application for T cell lymphoma, particularly cutaneous T cell lymphoma (CTCL), has been limited. Barriers to effective CAR-T cell th
Externí odkaz:
https://doaj.org/article/12eee23b654848a19939caf487e9b21b
Autor:
Runzhe Shu, Vera J. Evtimov, Maree V. Hammett, Nhu-Y N. Nguyen, Junli Zhuang, Peter J. Hudson, Maureen C. Howard, Aleta Pupovac, Alan O. Trounson, Richard L. Boyd
Publikováno v:
Molecular Therapy: Oncolytics, Vol 20, Iss , Pp 325-341 (2021)
Chimeric antigen receptor (CAR) T cells have revolutionized blood cancer immunotherapy; however, their efficacy against solid tumors has been limited. A common mechanism of tumor escape from single target therapies is downregulation or mutational los
Externí odkaz:
https://doaj.org/article/dcc5fdf677de4b70926700b77c4bfd6d
Autor:
Richard L. Boyd, Nicholas Boyd, Vera Evtimov, Aleta Pupovac, Kellie Cartledge, Alan O Trounson, Huimin Cao
Publikováno v:
Cells
Volume 10
Issue 10
Cells, Vol 10, Iss 2631, p 2631 (2021)
Volume 10
Issue 10
Cells, Vol 10, Iss 2631, p 2631 (2021)
Cellular immunotherapy is revolutionizing cancer treatment. However, autologous transplants are complex, costly, and limited by the number and quality of T cells that can be isolated from and expanded for re-infusion into each patient. This paper dem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77b3d784fd45ea748e9f7e4640134312
Autor:
Richard L. Boyd, Aleta Pupovac, Nicholas Boyd, Rasa Islam, Alan O Trounson, Vera Evtimov, Runzhe Shu
Publikováno v:
Cells, Vol 10, Iss 1058, p 1058 (2021)
Cells
Cells
Natural killer (NK) cells are potent innate immune system effector lymphocytes armed with multiple mechanisms for killing cancer cells. Given the dynamic roles of NK cells in tumor surveillance, they are fast becoming a next-generation tool for adopt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b74a2242ec4268ad0206c33fcc0fca5
https://www.mdpi.com/2073-4409/10/5/1058
https://www.mdpi.com/2073-4409/10/5/1058
Autor:
Maureen C. Howard, Alan O Trounson, Runzhe Shu, Vera Evtimov, Aleta Pupovac, Maree V. Hammett, Junli Zhuang, Nhu-Y N. Nguyen, Peter John Hudson, Richard L. Boyd
Publikováno v:
Molecular Therapy Oncolytics
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 325-341 (2021)
Molecular Therapy: Oncolytics, Vol 20, Iss, Pp 325-341 (2021)
Chimeric antigen receptor (CAR) T cells have revolutionized blood cancer immunotherapy; however, their efficacy against solid tumors has been limited. A common mechanism of tumor escape from single target therapies is downregulation or mutational los
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7cc00f82623a69b5255e5d818517c96
https://pubmed.ncbi.nlm.nih.gov/33614914
https://pubmed.ncbi.nlm.nih.gov/33614914
Autor:
Alan O Trounson, Hu Li, Qiuli Fu, Wei Zhao, Xudong Wang, Taylor M. Weiskittel, Cristina Correia, Ke Yao, Lin Tian, Jin Zhang, Anhua Lei
Publikováno v:
iScience
iScience, Vol 23, Iss 6, Pp 101162-(2020)
iScience, Vol 23, Iss 6, Pp 101162-(2020)
Despite progress in developing cell therapies, such as T cell or stem cell therapies to treat diseases, immunoincompatibility remains a major barrier to clinical application. Given the fact that a host's immune system may reject allogeneic transplant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a675612d9730815a4e0f66680fb75fe
http://europepmc.org/articles/PMC7270609
http://europepmc.org/articles/PMC7270609
Publikováno v:
Nature Biomedical Engineering. 2:797-809
The clinical translation of promising products, technologies and interventions from the disciplines of nanomedicine and cell therapy has been slow and inefficient. In part, translation has been hampered by suboptimal research practices that propagate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bcd44e24a72eff419ff473814261284
https://doi.org/10.1038/s41551-018-0314-y
https://doi.org/10.1038/s41551-018-0314-y
Autor:
Andrew J. French, Alan O Trounson
Publikováno v:
Expert Opinion on Drug Discovery. 13:1071-1074
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ea28b31a0a81ad732230da34ef53385
https://doi.org/10.1080/17460441.2018.1540585
https://doi.org/10.1080/17460441.2018.1540585
Publikováno v:
Cell Stem Cell. 24:508-510
In this issue of Cell Stem Cell, Xu et al. (2019) demonstrate that editing iPSCs' major histocompatibility antigens may potentially provide a small set of universally compatible stem cell lines for therapies. However, these modifications may result i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e19a13f74ea4f4b2e4a2fd0b8cf02893
https://doi.org/10.1016/j.stem.2019.03.003
https://doi.org/10.1016/j.stem.2019.03.003